Starpharma Holdings Ltd is a leading biopharmaceutical company driven by innovation and a commitment to improving lives through advanced pharmaceutical solutions. The company's core values revolve around scientific excellence, integrity, and a strong sense of social responsibility. With a focus on research and development, Starpharma strives to deliver breakthrough therapies and technologies in the fields of pharmaceuticals, personal care products, and agrochemicals. The corporate philosophy of Starpharma is centered on collaboration with partners and stakeholders to enhance patient outcomes and create value for shareholders. Through its dedication to transformative healthcare solutions, Starpharma is poised to revolutionize the industry and make a positive impact globally.

Starpharma Holdings Ltd is primarily present in Australia.

In recent years, Starpharma Holdings Ltd has achieved several significant milestones. The company successfully secured regulatory approvals for VivaGel®, its antiviral gel designed to prevent the transmission of HIV and genital herpes. Moreover, Starpharma forged an agreement with AstraZeneca, a leading pharmaceutical company, to explore the potential use of Starpharma's proprietary dendrimer technology in cancer treatment. Additionally, the company received strong market response for its VivaGel® products, leading to successful commercialization efforts and expanding its reach globally. Starpharma Holdings Ltd continues to make remarkable strides in the pharmaceutical industry through its innovative drug delivery and nanotechnology platforms.

Starpharma Holdings Ltd is a leading biopharmaceutical company with a rich history and background. Founded in 1996 and headquartered in Melbourne, Australia, Starpharma is focused on developing innovative pharmaceutical products and technologies. The company specializes in the design, development, and commercialization of dendrimer-based applications, particularly in the field of drug delivery and diagnostics. With a strong and experienced management team, Starpharma has achieved significant milestones and breakthroughs in the medical industry. The company's commitment to research and development has led to the creation of revolutionary products that address unmet medical needs. As Starpharma Holdings Ltd continues to grow and expand its portfolio, it remains a prominent player in the biopharmaceutical industry.

The main competitors of Starpharma Holdings Ltd in the market include other pharmaceutical companies such as Johnson & Johnson, Pfizer Inc., Novartis AG, and Merck & Co., Inc. These companies operate in similar industries and compete with Starpharma Holdings Ltd in areas such as research and development, product innovation, and market share. However, Starpharma Holdings Ltd stands out due to its unique expertise in dendrimer technology and the development of innovative pharmaceutical products.

Starpharma Holdings Ltd is primarily active in the healthcare and pharmaceutical industries.

Starpharma Holdings Ltd is a leading pharmaceutical company, specializing in the development and commercialization of innovative products for the pharmaceutical, life-science, and biotechnology sectors. The company's business model revolves around creating value through the advancement of their proprietary drug delivery platforms, such as VivaGel and DEP, which enhance the efficacy and safety of a range of therapeutics. Starpharma Holdings Ltd also generates revenue by partnering with global pharmaceutical companies to license their technology. With a strong focus on research and development, Starpharma Holdings Ltd aims to revolutionize drug delivery systems and improve patient outcomes in various therapeutic areas, positioning itself as a leader in the pharmaceutical industry.

De Starpharma Holdings K/W is -5,54.

De Starpharma Holdings KUV is 4,64.

De AlleAktien Kwaliteitsscore voor Starpharma Holdings is 4/10.

De Starpharma Holdings omzet is 9,76 mln. AUD.

De Starpharma Holdings winst is -8,17 mln. AUD.

Starpharma Holdings Ltd is an Australian biotechnology company based in Melbourne. The company operates in the fields of pharmaceuticals, biotechnology, and nanotechnology, focusing on the development and marketing of innovative technologies and medicines for the treatment of diseases. Its core areas of business include the development of micro-particles and polymers for artificial insemination, the development of virus and bacteria blockers for protection against sexually transmitted diseases, and the development of nano-antibodies for cancer treatment. Starpharma's products include VivaGel, a micro-particle foam used in artificial insemination, and Vivagel, a vaginal gel used as an effective measure against sexually transmitted diseases. The company also develops cancer drugs based on nanotechnology, such as DEP™, a patented technology for delivering cancer drugs using dendrimer nanoparticles. Starpharma has a partnership with AstraZeneca for the development and marketing of DEP™-based cancer drugs. The company's business model focuses on developing and marketing innovative technologies and medicines in the areas of artificial insemination, sexually transmitted diseases, and cancer treatment. The success of its business development depends on its ability to translate scientific advancements into tailored products, promote scientific progress through rapid innovation and global presence, and convince potential customers of the effectiveness of these products.

Starpharma Holdings keert een dividend van 0 AUD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Starpharma Holdings of het bedrijf keert geen dividend uit.

De ISIN van Starpharma Holdings is AU000000SPL0.

Het WKN van Starpharma Holdings is 796461.

De ticker van Starpharma Holdings is SPL.AX.

Binnen de laatste 12 maanden betaalde Starpharma Holdings een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Starpharma Holdings naar verwachting een dividend van 0 AUD betalen.

De dividendrendement van Starpharma Holdings is momenteel .

Starpharma Holdings betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Starpharma Holdings betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 AUD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Starpharma Holdings wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Starpharma Holdings van 2-12-2024 ter hoogte van 0 AUD te ontvangen, moest je het aandeel voor de ex-datum op 2-12-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 2-12-2024.

In het jaar 2023 heeft Starpharma Holdings 0 AUD aan dividenden uitgekeerd.

De dividenden van Starpharma Holdings worden in AUD uitgekeerd.